SEC Tracker
Get the app

Keros Therapeutics KROS

Keith Regnante (Officer) plans to sell 40,000 KROS shares, about $1.8M

Form
144
Filed
Importance
Routine
  1. Approximate sale date: Jan 4, 2024
  2. Broker: UBS Financial Services, Inc.
  3. Shares acquired by: Exercise of stock options
  4. 10b5-1 plan adopted: Mar 8, 2023

All of Keith Regnante's insider filings, holdings and planned sales

Form 4s that likely executed this notice (SEC Tracker's match by person, company, dates and shares):

  • Sold 40,000 shares at $45.29 on Jan 4, 2024 · Form 4

Written from the Form 144 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Keros Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Zevra Therapeutics ZVRA public float $455M, Jun 30, 2025
  2. Theravance Biopharma TBPH public float $449M, Jun 30, 2025
  3. aTYR PHARMA ATYR public float $464M, Jun 30, 2025
  4. Arvinas ARVN public float $469M, Jun 30, 2025
  5. Arbutus Biopharma ABUS public float $472M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.